进展期胃癌术后应用多西他赛联合卡培他滨化疗及同步放疗的疗效观察

Observation on Efficacy of Docetaxel Combined with Capecitabine Chemotherapy and Concurrent Radiochemotherapy in Advanced Gastric Cancer After Surgery

目的:探讨进展期胃癌根治术后予以多西他赛联合卡培他滨化疗及同步放疗的疗效。方法:选取2013年10月—2015年3月湖北省公安县人民医院收治的进展期胃癌根治术后患者76例作为研究对象,以随机数字表法分为观察组和对照组各38例。观察组患者采用多西他赛联合卡培他滨化疗并同步放疗;对照组患者采用多西他赛+奥沙利铂+氟尿嘧啶/醛氢叶酸的单纯化疗方案,比较2组患者的1、3年生存率及不良反应发生情况。结果:观察组患者1、3年生存率分别为84.21%(32/38)、55.26%(21/38),对照组分别为63.16%(24/38)、28.95%(11/38),2组的差异有统计学意义(P<0.05);观察组患者的不良反应发生率为76.32%(29/38),对照组为71.05%(27/38),2组的差异无统计学意义(P>0.05)。结论:进展期胃癌根治术后采用多西他赛联合卡培他滨化疗并同步放疗与术后单纯化疗相比,提高患者的生存率。

OBJECTIVE ：To probe into the efficacy of docetaxel （TXT） combined with capecitabine chemotherapy and concurrent radiochemotherapy in advanced gastric cancer after surgery. METHODS： 76 patients with advanced gastric cancer admitted into Gongan County People＇s Hospital of Hubei Provence from Oct. 2013 to Mar. 2015 were selected to be divided into observation group and control group via the random number table, with 38 cases in each. The observation group were treated with TXT combined with capecitabine chemotherapy and concurrent radiotherapy; while the control group received TXT and oxaliplatin （L-OHP） ＋ fluorouracil （5-FU）/leucovorin （CF） chemotherapy. 1-year and 3-year survival rate, incidence of adverse drug reactions were compared between two groups. RESULTS： 1-year and 3-year survival rate of observation group were 84.21% （32/38） and 55.26% （21/38）, and control group were 63.16% （24/38） and 28.95% （11/38）, with statistically significant difference （P 〈 0.05 ）. The incidence of adverse drug reactions of observation group was 76.32% （29/38）, and control group was 71.05% （27/38）, the difference was not statistically significant （ P 〉 0.05 ）. CONCLUSIONS： Compared with single chemotherapy, TXT combined with capecitabine chemotherapy and concurrent radiochemotherapy in advanced gastric cancer after surgery is more effective, which can improve the survival rate of patients.